Haemonetics Corporation (HAE)
NYSE: HAE · Real-Time Price · USD
78.78
+1.38 (1.78%)
Jul 24, 2026, 4:00 PM EDT - Market closed
Haemonetics Financials Overview
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 28, 2026 | Mar '26 Mar 28, 2026 | Mar '25 Mar 29, 2025 | Mar '24 Mar 30, 2024 | Apr '23 Apr 1, 2023 | Apr '22 Apr 2, 2022 |
Revenue Revenue Growth | 1,334 | 1,334 | 1,361 | 1,309 | 1,169 | 993.2 |
Revenue Growth | -1.97% | -1.97% | 3.96% | 12.01% | 17.67% | 14.10% |
Gross Profit Gross Profit Growth | 787.59 | 787.59 | 748.96 | 691.55 | 615.1 | 505.5 |
Operating Income Operating Income Growth | 156.73 | 156.73 | 221.82 | 164.88 | 156.03 | 80.75 |
Net Income Net Income Growth | 97.31 | 97.31 | 167.68 | 117.56 | 115.4 | 43.38 |
Earnings Per Share EPS Growth | 2.05 | 2.05 | 3.31 | 2.29 | 2.24 | 0.84 |
EPS Growth | -38.07% | -38.07% | 44.54% | 2.23% | 166.67% | -45.81% |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 28, 2026 | Mar '26 Mar 28, 2026 | Mar '25 Mar 29, 2025 | Mar '24 Mar 30, 2024 | Apr '23 Apr 1, 2023 | Apr '22 Apr 2, 2022 |
Plasma Plasma Growth | 524.46 | 524.46 | 535.43 | 569.54 | 500.49 | 351.95 |
Blood Center Blood Center Growth | 221.27 | 221.27 | 261.12 | 283.23 | 289.37 | 294.54 |
Hospital Hospital Growth | 588.3 | 588.3 | 564.27 | 456.29 | 378.21 | 321.58 |
Revenue (Total) Revenue (Total) Growth | 1,334 | 1,334 | 1,361 | 1,309 | 1,169 | 993.2 |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 28, 2026 | Mar '26 Mar 28, 2026 | Mar '25 Mar 29, 2025 | Mar '24 Mar 30, 2024 | Apr '23 Apr 1, 2023 | Apr '22 Apr 2, 2022 |
Cash & Investments Cash & Investments Growth | 245.44 | 245.44 | 306.76 | 178.8 | 284.47 | 259.5 |
Total Debt Total Debt Growth | 1,225 | 1,225 | 1,225 | 807.79 | 765.89 | 773.59 |
Net Cash (Debt) Net Cash Growth | -979.14 | -979.14 | -918.03 | -628.99 | -481.42 | -514.09 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -20.68 | -20.68 | -18.10 | -12.24 | -9.36 | -10.01 |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 28, 2026 | Mar '26 Mar 28, 2026 | Mar '25 Mar 29, 2025 | Mar '24 Mar 30, 2024 | Apr '23 Apr 1, 2023 | Apr '22 Apr 2, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 293.22 | 293.22 | 181.73 | 181.75 | 273.06 | 172.26 |
Capital Expenditures CapEx Growth | -32.78 | -32.78 | -39.28 | -38.13 | -191.33 | -96.51 |
Free Cash Flow Free Cash Flow Growth | 260.44 | 260.44 | 142.45 | 143.63 | 81.73 | 75.75 |
Free Cash Flow Growth | 82.83% | 82.83% | -0.82% | 75.73% | 7.89% | 5.56% |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 28, 2026 | Mar '26 Mar 28, 2026 | Mar '25 Mar 29, 2025 | Mar '24 Mar 30, 2024 | Apr '23 Apr 1, 2023 | Apr '22 Apr 2, 2022 |
Gross Margin | 59.04% | 59.04% | 55.04% | 52.83% | 52.63% | 50.90% |
Operating Margin | 11.75% | 11.75% | 16.30% | 12.60% | 13.35% | 8.13% |
Pretax Margin | 9.60% | 9.60% | 15.58% | 11.60% | 12.10% | 6.41% |
Profit Margin | 7.29% | 7.29% | 12.32% | 8.98% | 9.87% | 4.37% |
FCF Margin | 19.52% | 19.52% | 10.47% | 10.97% | 6.99% | 7.63% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 27, 2026 | Mar '26 Mar 28, 2026 | Mar '25 Mar 29, 2025 | Mar '24 Mar 30, 2024 | Apr '23 Apr 1, 2023 | Apr '22 Apr 2, 2022 |
PE Ratio | 38.43 | 26.36 | 19.09 | 37.27 | 36.94 | 76.01 |
Forward PE | 15.10 | 10.46 | 13.21 | 20.49 | 25.45 | 23.82 |
P/FCF Ratio | 13.75 | 9.39 | 21.39 | 30.18 | 51.08 | 43.09 |
PS Ratio | 2.68 | 1.83 | 2.24 | 3.31 | 3.57 | 3.29 |